POPULATION AND PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING OF RISDIPLAM IN INFANTS, CHILDREN, AND ADULTS WITH SPINAL MUSCULAR ATROPHY (SMA).

被引：0
|
作者：
Cleary, Y. [1 ,2 ]
Kletzl, H. [1 ]
Grimsey, P. [3 ]
Frey, N. [1 ]
Baumann, H. Silber [1 ]
Stillhart, C. [1 ]
Poirier, A. [1 ]
Heinig, K. [1 ]
Fowler, S. [1 ]
Ogungbenro, K. [2 ]
Aarons, L. [2 ]
Galetin, A. [2 ]
Gertz, M. [1 ]
机构：
[1] F Hoffmann La Roche, Grenzacherstr, Basel, Switzerland
[2] Univ Manchester, Manchester, Lancs, England
[3] F Hoffmann La Roche, Welwyn Garden City, England
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2021年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PI-018
引用
收藏
页码：S10 / S10
页数：1
相关论文
共 50 条
  • [1] ESTIMATION OF IN VIVO FMO3 ONTOGENY BY MECHANISTIC POPULATION PHARMACOKINETIC MODELING OF RISDIPLAM IN INFANTS, CHILDREN AND ADULTS WITH SPINAL MUSCULAR ATROPHY.
    Cleary, Y.
    Kletzl, H.
    Grimsey, P.
    Ogungbenro, K.
    Aarons, L.
    Galetin, A.
    Gertz, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S70 - S70
  • [2] RAINBOWFISH: A study of risdiplam in infants with presymptomatic spinal muscular atrophy (SMA)
    Servais, L.
    Al-Muhaizea, M.
    Farrar, M.
    Nelson, L.
    Prufer, A.
    Finkel, R.
    Wang, Y.
    Zanoteli, E.
    El-Khairi, M.
    Gerber, M.
    Gorni, K.
    Kletzl, H.
    Palfreeman, L.
    Scalco, R.
    Bertini, E.
    NEUROMUSCULAR DISORDERS, 2021, 31 : S48 - S48
  • [3] MODEL-BASED INVESTIGATION OF CYP3A ENZYME INACTIVATION EFFECT OF RISDIPLAM IN INFANTS, CHILDREN, AND ADULTS WITH SPINAL MUSCULAR ATROPHY (SMA).
    Cleary, Y.
    Gertz, M.
    Grimsey, P.
    Guenther, A.
    Heinig, K.
    Ogungbenro, K.
    Aarons, L.
    Galetin, A.
    Kletzl, H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S9 - S10
  • [4] RAINBOWFISH: A study of risdiplam (RG7916) in infants with presymptomatic spinal muscular atrophy (SMA)
    Servais, L.
    Bertini, E.
    Al-Muhaizea, M.
    Nelson, L.
    Prufer, A.
    Vlodavets, D.
    Wang, Y.
    Zanoteli, E.
    Burke, L.
    El-Khairi, M.
    Gorni, K.
    Kletzl, H.
    Gerber, M.
    Scalco, R.
    Finkel, R.
    NEUROMUSCULAR DISORDERS, 2020, 30 : S127 - S127
  • [5] Real-world treatment with risdiplam in adults with spinal muscular atrophy (SMA): a multicenter study
    Guittari, C.
    Candrilli, S.
    Miles, L.
    Simpson, A.
    Shapouri, S.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S164 - S164
  • [6] Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates
    Kovar, Lukas
    Schraepel, Christina
    Selzer, Dominik
    Kohl, Yvonne
    Bals, Robert
    Schwab, Matthias
    Lehr, Thorsten
    PHARMACEUTICS, 2020, 12 (06) : 1 - 22
  • [7] RAINBOWFISH: A Study of Risdiplam in Newborns with Presymptomatic Spinal Muscular Atrophy (SMA)
    Finkel, Richard S.
    Al-Muhaizea, Mohammad
    Farrar, Michelle A.
    Nelson, Leslie
    Prufer, Alexandra
    Servais, Laurent
    Wang, Yi
    Zanoteli, Edmar
    Palfreeman, Laura
    El-Khairi, Muna
    Gorni, Ksenija
    Kletzl, Heidemarie
    Gerber, Marianne
    Scalco, Renata S.
    Bertini, Enrico
    NEUROLOGY, 2021, 96 (15)
  • [8] Children with spinal muscular atrophy treated with nusinersen/risdiplam
    Chacko, A.
    Sly, P.
    Deegan, S.
    Young, E.
    Gauld, L.
    RESPIROLOGY, 2023, 28 : 204 - 205
  • [9] Children With Spinal Muscular Atrophy Treated With Nusinersen/Risdiplam
    Chacko, A.
    Sly, P. D.
    Deegan, S.
    Young, E.
    Gauld, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [10] Paracetamol and its metabolites in children and adults with spinal muscular atrophy - a population pharmacokinetic model
    Zhao, Qiaolin
    Naume, Marie Mostue
    de Winter, Brenda C. M.
    Krag, Thomas
    Haslund-Krog, Sissel Sundell
    Revsbech, Karoline Lolk
    Vissing, John
    Holst, Helle
    Moller, Morten Hylander
    Hornsyld, Tessa Munkeboe
    Duno, Morten
    Hoei-Hansen, Christina Engel
    Born, Alfred Peter
    Jensen, Per Bo
    Orngreen, Mette Cathrine
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2025,
12345